Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CHRO OTCMKTS:ENZN NASDAQ:OMGA OTCMKTS:PMCBD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHROChromocell Therapeutics$1.34+6.3%$10.05$4.50▼$38.00$8.69M3.6345,567 shs194,032 shsENZNEnzon Pharmaceuticals$0.10-9.1%$0.09$0.06▼$0.24$8.16M0.36122,732 shs110,301 shsOMGAOmega Therapeutics$0.13-21.8%$0.12$0.10▼$2.15$6.92M1.653.60 million shs4.81 million shsPMCBDPharmaCyte Biotech$1.10$1.07$5.56▼$55.50$1.84M0.278,831 shs13,405 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHROChromocell Therapeutics0.00%0.00%-88.93%-90.07%-87.87%ENZNEnzon Pharmaceuticals-9.09%-11.27%+18.48%0.00%-38.29%OMGAOmega Therapeutics0.00%0.00%0.00%0.00%-92.98%PMCBDPharmaCyte Biotech-0.90%+0.92%+7.84%-8.71%-49.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHROChromocell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOMGAOmega Therapeutics2.1277 of 5 stars3.40.00.00.00.61.71.3PMCBDPharmaCyte BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHROChromocell Therapeutics 0.00N/AN/AN/AENZNEnzon Pharmaceuticals 0.00N/AN/AN/AOMGAOmega Therapeutics 2.80Moderate Buy$8.506,700.00% UpsidePMCBDPharmaCyte Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/AENZNEnzon Pharmaceuticals$30K247.37$0.01 per share10.49$0.04 per share2.50OMGAOmega Therapeutics$8.10M0.85N/AN/A$1.05 per share0.12PMCBDPharmaCyte BiotechN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/AENZNEnzon Pharmaceuticals$780K-$0.01N/A∞N/AN/A-22.19%-1.28%8/6/2025 (Estimated)OMGAOmega Therapeutics-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%N/APMCBDPharmaCyte Biotech-$3.83MN/A0.00∞N/AN/A-49.09%-43.39%N/ALatest PMCBD, ENZN, OMGA, and CHRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ENZNEnzon PharmaceuticalsN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHROChromocell TherapeuticsN/AN/AN/AN/AN/AENZNEnzon PharmaceuticalsN/AN/AN/AN/AN/AOMGAOmega TherapeuticsN/AN/AN/AN/AN/APMCBDPharmaCyte BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHROChromocell TherapeuticsN/A0.600.60ENZNEnzon PharmaceuticalsN/A82.1782.17OMGAOmega Therapeutics1.001.611.61PMCBDPharmaCyte BiotechN/A4.904.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHROChromocell Therapeutics77.96%ENZNEnzon PharmaceuticalsN/AOMGAOmega Therapeutics97.47%PMCBDPharmaCyte Biotech0.02%Insider OwnershipCompanyInsider OwnershipCHROChromocell Therapeutics16.40%ENZNEnzon Pharmaceuticals0.40%OMGAOmega Therapeutics8.50%PMCBDPharmaCyte BiotechN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHROChromocell Therapeutics46.49 million5.04 millionN/AENZNEnzon PharmaceuticalsN/A74.21 million73.92 millionNot OptionableOMGAOmega Therapeutics12055.37 million50.66 millionOptionablePMCBDPharmaCyte BiotechN/A1.67 millionN/ANot OptionablePMCBD, ENZN, OMGA, and CHRO HeadlinesRecent News About These CompaniesPharmaCyte Biotech (PMCB) Earnings Dates & ReportsSeptember 27, 2024 | investing.comInternational Life Sciences & Biotech ConferenceSeptember 12, 2024 | bisnow.comBPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024March 19, 2024 | investorplace.comPharmaCyte Biotech Inc (PMCB)February 22, 2024 | investing.com2nd Shareholder Lawsuit Filed Against Biotech CompanyJanuary 16, 2024 | law.comLExploring beauty’s biotech frontierOctober 27, 2023 | ft.comThe biotech scorecard for the fourth quarter: 16 stock-moving events to watchOctober 9, 2023 | statnews.comSPMCB PharmaCyte Biotech, Inc.May 25, 2023 | seekingalpha.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferMay 11, 2023 | marketwatch.comWhy Do So Many Biotech Startups Fail?May 6, 2023 | alleywatch.comABaltimore Biotech NewsApril 28, 2023 | bizjournals.comBiotech Study BreakApril 3, 2023 | princeton.eduPBiden sees future in ag biotech; food safety includedApril 3, 2023 | foodsafetynews.comFBiotech & HealthMarch 30, 2023 | techcrunch.comTAlamance Community College celebrates grand opening of new multi-million dollar Biotech CenterMarch 27, 2023 | wunc.orgWTalks Underway to Stop Implementation of Mexican Biotech BanDecember 1, 2022 | fb.orgFPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueOctober 7, 2022 | finance.yahoo.comBLACK BIRD BIOTECH INCSeptember 28, 2022 | finanznachrichten.deBharat Biotech's Nasal Vaccine Against Covid-19 Cleared For UseSeptember 14, 2022 | ndtv.comNPharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationJuly 28, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCBD, ENZN, OMGA, and CHRO Company DescriptionsChromocell Therapeutics NYSE:CHRO$1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Enzon Pharmaceuticals OTCMKTS:ENZN$0.10 -0.01 (-9.09%) As of 07/9/2025 03:26 PM EasternEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Omega Therapeutics NASDAQ:OMGA$0.12 -0.03 (-21.83%) Closing price 02/24/2025Extended Trading$0.12 0.00 (0.00%) As of 02/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.PharmaCyte Biotech OTCMKTS:PMCBD$1.10 0.00 (0.00%) As of 07/8/2025PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
